Late Phase II Study of TS-142 in Patients With Insomnia
Latest Information Update: 13 Mar 2022
At a glance
- Drugs Vornorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 13 Dec 2021 Status changed from recruiting to completed.
- 03 Aug 2020 Planned initiation date (Estimated date of first participant enrollement) changed from 20 Jul 2020 to 1 Sep 2020.
- 03 Aug 2020 Status changed from not yet recruiting to recruiting.